Shots:
- The US FDA has approved Icotyde for the treatment of pts (≥12yrs., ≥40kg) with mod. to sev. plaque PsO who are candidates for systemic therapy or phototherapy
- Approval was backed by P-III (ICONIC-TOTAL, ICONIC LEAD, ICONIC-ADVANCE 1 & 2) trials, where Icotyde met all 1EP across all 4 trials (n=2,500). In the head-to-head studies, ~70% pts achieved IGA 0/1 & 55% reached PASI 90 at Wk. 16
- Icotyde (JNJ-2113) is also being assessed in ICONIC-PsA 1 & 2 (vs PBO) for active psoriatic arthritis, ICONIC-UC for mod. to sev. active ulcerative colitis & ICONIC-CD for mod. to sev. active Crohn’s disease
Ref: J&J | Image: J&J | Press Release
Related News: J&J Reports P-III Trial Outcomes Showing Tecvayli Monotherapy Extends PFS and OS in R/R Multiple Myeloma
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
